Keros Therapeutics (KROS) Capital Expenditures (2019 - 2025)

Keros Therapeutics has reported Capital Expenditures for 7 years, with the latest figure at -$1.4 million in Q4 2025.

• For the quarter ending Q4 2025, Capital Expenditures fell 588.58% year-over-year to -$1.4 million; the trailing twelve-month figure through Dec 2025 stood at $5000.0 (down 99.74% YoY), and the FY2025 full-year result was $5000.0, down 99.74% from the prior year.
• Capital Expenditures for Q4 2025 stood at -$1.4 million, down from $1.4 million in the prior quarter.
• The five-year high for Capital Expenditures was $1.6 million in Q3 2024, with the low at -$1.4 million in Q4 2025.
• Historically, Capital Expenditures has averaged $252631.6 across 5 years, with a median of $159000.0 in 2021.
• Annual changes were most pronounced in 2021 — Capital Expenditures soared 2471.43% — and 2023, when it sank 11836.36%.
• Keros Therapeutics' Capital Expenditures stood at $159000.0 in 2021, then jumped by 672.33% to $1.2 million in 2022, then sank by 56.11% to $539000.0 in 2023, then slumped by 46.38% to $289000.0 in 2024, then tumbled by 588.58% to -$1.4 million in 2025.
• The last three Capital Expenditures figures came in at -$1.4 million (Q4 2025), $1.4 million (Q3 2025), and -$551000.0 (Q2 2025), per Business Quant data.